Zelluläre Mechanismen der Toleranzinduktion bei der spezifischen Immuntherapie mit Allergoiden
Allergische Erkrankungen haben in den letzten Jahren in Industrie- sowie Entwicklungsländern kontinuierlich zugenommen. Die aktuellen Behandlungsmöglichkeiten beschränken sich hauptsächlich auf symptomatische Therapieverfahren. Die einzige kurative Therapieform ist derzeit die spezifische Immunt...
Saved in:
Main Author: | |
---|---|
Contributors: | |
Format: | Doctoral Thesis |
Language: | German |
Published: |
Philipps-Universität Marburg
2013
|
Subjects: | |
Online Access: | PDF Full Text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
There is a continuous increase of allergic diseases in industrial countries as well
as in developing countries. While most available therapies are constricted to
symptomatic treatments, only the specific immunotherapy (SIT) can be
considered as curative.
Different forms of allergens and modes of application are utilized. Allergoids are
modified types of allergens. They should be characterized by a reduced
allergenicity and received immunogenicity. Thereby a saver and faster
escalation of the application rate in comparison to natural allergens should be
possible.
Although fundamental research has progressed in the past decades elucidating
the development of allergic diseases, the definite mechanism of how SIT
induces immuntolerance is still a focus of intensive research.
The aim of this study was the exploration of immune alterations during the firstyear
SIT with an allergoid (Depigoid®) in birch-pollen allergic persons. Seven
patients with birch-pollen allergy were included in this study. The clinical
efficiency of SIT was evaluated by different questionnaires and skin tests.
Allergen-specific IgE, total IgE and allergen-specific IgG4 was detected by
ImmunoCap. In addidtion changes of the quantity of Bet v 1- (major-allergen of
birch) specific Th1-, Th2- and Tr1-cells were detected by ELISPOT assay after
allergenspecific-stimulation. Furthermore CD4+CD25+CD127low Treg were
quantified by cytometric measurement and the proliferation of PBMC after
stimulation with Bet v 1 measured.
While patients showed an improvement of their medical condition, there were
only marginal immunologic changes detected. Immunglobulin measurements
showed only a trend of decrease for allergenspecific IgE antibodies, but almost
constant data for total IgE and allergen-specific IgG4. Counts for Bet v 1-
specific cells showed an increase in the first month of therapy and at the end of
the first therapy year. In contrast, a decrease of Th1-cells and consequently an
increase of Th2/Th1-quotient could be detected. Tr1-measurements showed an
increase of Tr1-cells, but no changes of the fraction of CD4+CD25+CD127low-
Treg.
In summary the present study suggest that in comparison to the results of SITstudies
with native allergens different immune mechanisms are responsible for
tolerance induction through SIT with allergoid. Further studies with a greater
number of subjects should help to elucidate these mechanisms in more detail.